In the Age of AI, Interoperability Isn’t Enough: Why Healthcare Needs Shared Understanding, Not Just Shared Data
The industry needs a framework that can translate clinical nuance into a consistent, trusted representation across systems and use cases.
The Myth of Insurance Networks
How America's outdated insurance model is failing at its most important job
Smoking Cessation’s Quiet Design Failure
The gap between how nicotine use has evolved and how cessation treatment has evolved is a meaningful part of why quit rates have plateaued.
OIG: 3 Largest MA Insurers Deny Prior Auth Requests at High Rates for Long-Term Acute Care, Inpatient Rehab
An OIG report found that the three largest Medicare Advantage insurers denied prior authorization requests for long-term acute care and inpatient rehabilitation at higher rates than other MA plans in 2024.
Amgen Defends Rare Disease Drug in FDA Crosshairs
FDA concerns about Amgen’s Tavneos were sparked by securities fraud litigation against ChemoCentryx, the company that originally developed the rare disease drug. The FDA wants to withdraw Tavneos’s approval, citing safety risks and alleged manipulation of the drug’s clinical trial data.